Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eyantra Ventures Ltd reported strong revenue growth but a sharp collapse in profitability for FY2026. Standalone revenue surged 145% to Rs 6,750.21 Lacs (vs Rs 2,759.27 Lacs in FY25), but standalone net profit dropped 84% to Rs 26.53 Lacs (vs Rs 166.39 Lacs), indicating severe cost and margin pressures from the expansion. At consolidated level, the company swung to a net loss of Rs 475.05 Lacs (vs profit of Rs 75.07 Lacs in FY25), with consolidated revenue nearly tripling to Rs 9,422.41 Lacs. The auditors issued unmodified (clean) opinions on both standalone and consolidated financial statements, with no qualifications or adverse remarks. The company's consolidated results include its wholly-owned subsidiaries (Prismberry Technologies and Eyantra Ventures FZE) and an associate (Neuro And Spine Associates). The preferential issue of 18.75 lakh equity shares at Rs 800 each (raised Rs 1,386.85 Lacs out of Rs 1,500 Lacs) is partially deployed towards working capital and strategic investments.
Revenue growth is impressive at over 140%, but the steep profit decline and consolidated net loss signal that aggressive expansion is currently destroying bottom-line profitability. Investors should watch whether margins recover as the new hospital and healthcare operations scale.